You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 12, 2025

Suppliers and packagers for generic pharmaceutical drug: dextromethorphan hydrobromide; promethazine hydrochloride


✉ Email this page to a colleague

« Back to Dashboard


dextromethorphan hydrobromide; promethazine hydrochloride

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Pai Holdings PROMETHAZINE DM dextromethorphan hydrobromide; promethazine hydrochloride SYRUP;ORAL 040649 ANDA PAI Holdings, LLC dba PAI Pharma 0121-1070-04 118 mL in 1 BOTTLE (0121-1070-04) 2025-06-04
Pai Holdings PROMETHAZINE DM dextromethorphan hydrobromide; promethazine hydrochloride SYRUP;ORAL 040649 ANDA PAI Holdings, LLC dba PAI Pharma 0121-1070-16 473 mL in 1 BOTTLE (0121-1070-16) 2025-06-04
Pai Holdings PROMETHAZINE DM dextromethorphan hydrobromide; promethazine hydrochloride SYRUP;ORAL 040649 ANDA ATLANTIC BIOLOGICALS CORP. 17856-0155-1 72 CUP, UNIT-DOSE in 1 BOX, UNIT-DOSE (17856-0155-1) / 5 mL in 1 CUP, UNIT-DOSE 2020-10-05
Pai Holdings PROMETHAZINE DM dextromethorphan hydrobromide; promethazine hydrochloride SYRUP;ORAL 040649 ANDA A-S Medication Solutions 50090-6585-0 118 mL in 1 BOTTLE (50090-6585-0) 2020-10-05
Pai Holdings PROMETHAZINE DM dextromethorphan hydrobromide; promethazine hydrochloride SYRUP;ORAL 040649 ANDA NuCare Pharmaceuticals,Inc. 68071-3551-4 118 mL in 1 BOTTLE (68071-3551-4) 2020-10-05
Pai Holdings PROMETHAZINE DM dextromethorphan hydrobromide; promethazine hydrochloride SYRUP;ORAL 040649 ANDA Preferred Pharmaceuticals Inc. 68788-8100-1 118 mL in 1 BOTTLE (68788-8100-1) 2021-10-08
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers for the Pharmaceutical Drugs: Dextromethorphan Hydrobromide and Promethazine Hydrochloride

Last updated: August 2, 2025

Introduction

Dextromethorphan Hydrobromide and Promethazine Hydrochloride are prominent active pharmaceutical ingredients (APIs) widely used in prescription and over-the-counter medications. Dextromethorphan, primarily recognized as a cough suppressant, and Promethazine, a phenothiazine derivative, are integral to respiratory and allergy treatment regimens. The global supply chain for these APIs is complex, involving numerous manufacturers, intermediaries, and raw material suppliers. Understanding the landscape of suppliers is vital for pharmaceutical developers, distributors, and regulatory bodies aiming to ensure quality, reliability, and compliance.


Overview of Dextromethorphan Hydrobromide Suppliers

Manufacturers

  1. Boehringer Ingelheim

    • A leading global pharmaceutical company, Boehringer Ingelheim is a significant supplier of Dextromethorphan Hydrobromide, producing both active ingredients and finished dosage forms.
    • Their facilities are compliant with strict Good Manufacturing Practices (GMP), ensuring high-quality standards.
  2. Sun Pharmaceutical Industries Ltd.

    • One of India's largest pharmaceutical firms, Sun Pharma manufactures Dextromethorphan Hydrobromide for global export, including bulk APIs and formulations.
    • The company emphasizes quality and price competitiveness.
  3. Hubei Good International Pharmaceutical Co., Ltd.

    • Based in China, Hubei Good specializes in APIs, including Dextromethorphan, leveraging cost-efficient production capabilities.
    • Their facilities conform to cGMP standards, and they export widely across Asia, Africa, and Latin America.
  4. Jubilant Life Sciences

    • An Indian API producer, Jubilant supplies Dextromethorphan Hydrobromide to global markets, focusing on purity and consistency.
  5. Mithila Chemicals & Pharmaceuticals Ltd.

    • A smaller but notable supplier based in India, providing competitive pricing and reliable supply chains.

Raw Material Suppliers

Dextromethorphan Hydrobromide synthesis requires precursor chemicals like 3-methoxyphenylacetonitrile and specific intermediates. Key chemical suppliers include:

  • Huntsman Corporation
  • Lowe's Chemical
  • Xi'an Yuanhua Chemical Industry

These raw material vendors supply high-purity chemicals critical to ensure final API quality.


Overview of Promethazine Hydrochloride Suppliers

Manufacturers

  1. Aurolab (India)

    • A key producer of generic ophthalmic and injectable formulations, Aurolab supplies Promethazine Hydrochloride in bulk API form.
    • The company emphasizes affordable, high-quality APIs for emerging markets.
  2. Sino Biopharmaceutical Limited

    • Based in China, Sino Biopharmaceutical's API division supplies Promethazine Hydrochloride conforming to international standards.
  3. Laurus Labs

    • An Indian manufacturer with a diversified API portfolio, including Promethazine Hydrochloride, focusing on quality standards and supply security.
  4. Hubei Huayi Pharmaceutical Co., Ltd.

    • Offers Promethazine Hydrochloride API with compliance to cGMP, primarily targeting Asian markets.
  5. Mingxin Pharmaceutical Co., Ltd.

    • Supplies Promethazine Hydrochloride for global export, emphasizing affordability.

Raw Material and Intermediates Suppliers

The synthesis of Promethazine Hydrochloride involves chlorination and reduction steps using intermediates like phenothiazine derivatives. Suppliers include:

  • Jay Chemicals International
  • Shandong Jining Pharmaceutical Co., Ltd.
  • Cambridge Chemical Industries

These vendors provide intermediates necessary for plant-based synthesis.


Global Supply Chain Dynamics

The supply of Dextromethorphan Hydrobromide and Promethazine Hydrochloride hinges on:

  • Regulatory Standards: Suppliers must comply with cGMP, ISO, and other certifications. Chinese and Indian manufacturers dominate due to cost advantages and capacity.
  • Raw Material Availability: Fluctuations in raw material markets influence API pricing and availability.
  • Manufacturing Capacity: Capacity expansions by multinational corporations and regional companies affect supply stability.
  • Trade Policies: Tariffs, export restrictions, and international sanctions impact sourcing options, especially from China and India.

Key Factors for Buyers

  • Quality Assurance: Choose suppliers with robust quality certifications.
  • Regulatory Compliance: Ensure suppliers meet local and international standards.
  • Supply Consistency: Vendors with proven track records prevent stock outages.
  • Cost Competitiveness: Balance quality with economic considerations.
  • Customs and Logistics: Consider geopolitical factors affecting shipment and clearance.

Emerging Trends and Challenges

  • Increasing Regulatory Scrutiny: Authorities like the FDA and EMA intensify API manufacturing inspections, affecting supplier eligibility.
  • Supply Chain Disruptions: COVID-19 highlighted vulnerabilities, prompting diversification strategies.
  • Local Manufacturing Initiatives: Some regions develop domestic APIs to reduce dependency on import-heavy supply chains.
  • Environmental and Ethical Standards: Suppliers face pressure for sustainable practices and chemical handling transparency.

Conclusion

The supply landscape for Dextromethorphan Hydrobromide and Promethazine Hydrochloride remains concentrated predominantly among Indian and Chinese manufacturers, with several reputable global suppliers ensuring quality and capacity. Stakeholders should meticulously evaluate supplier certifications, production capacity, and compliance to mitigate risks and secure reliable access to these vital APIs.


Key Takeaways

  • The majority of Dextromethorphan Hydrobromide and Promethazine Hydrochloride come from Asia, primarily India and China, which dominate manufacturing and raw material supply.
  • Quality certifications like cGMP and ISO are critical for selecting dependable suppliers in the pharmaceutical supply chain.
  • Diversification of suppliers and geopolitical awareness are essential to prevent disruptions.
  • Monitoring regulatory changes can impact supplier sourcing and distribution strategies.
  • Sustainable and transparent manufacturing practices are increasingly influencing buyer decisions.

FAQs

1. Are there any major global API manufacturers for Dextromethorphan Hydrobromide and Promethazine Hydrochloride?
Yes. Boehringer Ingelheim and Jubilant Life Sciences are among the leading global manufacturers offering high-quality APIs, with several Chinese and Indian firms providing cost-effective options.

2. How can I verify the quality of an API supplier?
Verify their certifications (cGMP, ISO), review audit reports, request batch documentation, and consider third-party quality assessments or inspections.

3. What are the logistical challenges for sourcing these APIs internationally?
Challenges include customs clearance delays, trade restrictions, geopolitical tensions, documentation requirements, and transportation disruptions.

4. Is there a difference in API quality between Chinese and Indian manufacturers?
Quality varies by supplier; reputable companies from both countries adhere to international standards. Due diligence and certification verification are essential.

5. What is the outlook for the future supply of these APIs?
Supply is expected to remain stable, with ongoing capacity expansions. However, increasing regulatory oversight and supply chain diversification efforts may influence availability and pricing.


Sources

[1] U.S. Food and Drug Administration (FDA), API Certification Database, 2022.
[2] Indian Pharmaceutical Industry Data, Indian Pharma Export Council, 2021.
[3] Chinese Pharmaceuticals Annual Report, China Pharmaceutical Industry Association, 2022.
[4] Market Intelligence Reports, Global API Manufacturing Trends, 2022.
[5] WHO Prequalification of Medicines Programme, API Standards, 2022.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.